Lineage Cell Therapeutics Inc
TASE:LCTX
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.
OpRegen Progress: The OpRegen program continues to advance, with Genentech doubling clinical sites in the past year and expanding device innovation, which management views as positive signals.
New Partnerships: Lineage secured a collaboration with William Demant Invest to fund up to $12 million for its preclinical hearing loss program, validating its external funding strategy.
Cash Runway Extended: Cash position at $40.5 million now supports operations into Q2 2027, one quarter longer than previously guided, helped by partnership funding.
Financial Results: Q3 revenue was $3.7 million (down slightly YoY), and net loss was $29.8 million, largely due to a non-cash warrant liability adjustment.
CIRM Grant Update: Lineage is a finalist for a CIRM grant decision expected in December, which could provide up to $7 million in nondilutive funding for the OPC1 program.
Islet Cell Initiative: Early work on large-scale islet cell production for Type 1 Diabetes is ongoing, with a go/no-go decision expected next quarter.
Optionality & Strategy: Management reiterated discipline in expanding the asset portfolio, balancing internal development and partnerships based on cost of capital and risk.
